BioSpace News Archive

Captor Therapeutics S.A. announced its strategic objectives for the period 2023 to 2025 aimed at building a clinical stage, major international player in the rapidly growing TPD space.

While Electronic Health Records improve access to patient information, charting increases the clerical burden on physicians as medical documentation has been identified as a contributing factor to burnout.

Oxford BioTherapeutics Ltd. announces it has been honoured with two prestigious awards: the ‘Tech Company of the Year’ and the ‘Special Recognition Award’, at The Business Magazine’s fourth annual Thames Valley SME Growth 100 Awards.

NanOlogy LLC, a clinical-stage oncology company, announced issuance of a US patent titled: Local Delivery of Antineoplastic Particles in Combination with Systemic Delivery of Immunotherapeutic Agents for the Treatment of Cancer.

Axonics, Inc. is participating as a platinum sponsor of the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2023 Winter Meeting, which is being held in Nashville from March 7-11.

Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a corporate update.

CytoSorbents Corporation announces that hemoadsorption of antithrombotic drugs in cardiothoracic surgery has made its way into the new “2022 Guidelines for the Management of Severe Perioperative Bleeding” by the European Society of Anaesthesiology and Intensive Care and was published in the European Journal of Anaesthesiology last week.

Zimmer Biomet Holdings, Inc., a global medical technology leader, announced plans to unveil the latest enhancements to ZBEdge™ Dynamic Intelligence™ at the American Academy of Orthopaedic Surgeon’s 2023 Annual Meeting in Las Vegas.

Nevro Corp. (NYSE: NVRO) today announced that it has now initiated the U.S. full market launch of its HFX iQ spinal cord stimulation (SCS) system, following the completion of a successful limited market release.

Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for eplontersen, an investigational antisense medicine for the treatment of people living with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).